Trial reportIntensive care medicine1993
Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study.
Trial report in Intensive care medicine, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials.Critical care (London, England) · 2023Pooled it
- Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.The Cochrane database of systematic reviews · 2020Pooled it
- Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.The Cochrane database of systematic reviews · 2020Pooled it
- Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?Intensive care medicine · 2006Pooled it
- Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.Antimicrobial agents and chemotherapy · 1997Trial
- Renal replacement therapy in intensive care unit: a narrative review.Annals of intensive care · 2026Review
- How to Prolong Filter Life During Continuous Renal Replacement Therapy?Critical care (London, England) · 2022Review
- Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?Journal for immunotherapy of cancer · 2020Review
- Anemia, Blood Transfusion, and Filter Life Span in Critically Ill Patients Requiring Continuous Renal Replacement Therapy for Acute Kidney Injury: A Case-Control Study.Critical care research and practice · 2019Article
- Article
- Cooling and reduced risk of clotting within the extracorporeal continuous renal replacement circuit.Intensive care medicine · 2009Article
- Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass.Intensive care medicine · 2008Article
- Clinical review: Patency of the circuit in continuous renal replacement therapy.Critical care (London, England) · 2007Review
- Renal replacement therapy in the intensive care unit.Therapeutics and clinical risk management · 2005Article
- Continuous haemofiltration in the intensive care unit.Critical care (London, England) · 2000Review
- A review of continuous renal replacement therapy.Irish journal of medical science · 1994Review
- Clinical pharmacokinetics during continuous haemofiltration.Clinical pharmacokinetics · 1994Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare and contrast different heparin regimens for extracorporeal circuit anticoagulation in patients receiving acute continuous hemodiafiltration (ACHD).
designProspective controlled randomized comparisons of the following regimens: 1) Low dose (500 IU/h) pre-filter heparin versus regional anticoagulation in patients on continuous arteriovenous hemodiafiltration (CAVHD) via A-V shunt. 2) Low dose pre-filter heparin versus no anticoagulation in patients receiving CAVHD via femoral cannulae. 3) Low dose pre-filter heparin versus regional anticoagulation in patients on continuous veno-venous hemodiafiltration (CVVHD). 4) An assessment of the consequences of the use of no anticoagulant in patients predicted to be at high risk of hemorrhagic complications on treatment with CVVHD.
settingUniversity Teaching Hospital ICU. PATIENTS: 64 ICU patients with acute renal failure. MEASUREMENTS AND MAIN
resultsHaemofilter survival during shunt CAVHD was significantly prolonged by the use of regional anticoagulation compared to the use of low dose heparin (mean filter survival: 57.1 h versus 42.9 h; p < 0.05). In CAVHD using femoral cannulae, no significant differences in haemofilter survival were found between anticoagulation with low dose heparin and the use of no anticoagulant (mean filter survival: 55 h versus 52.5 h; NS). During CVVHD, regional anticoagulation compared to low dose heparin produced a trend towards prolonged filter life which was, however, not statistically significant (mean filter survival: 40.5 h versus 31.4 h; NS). In patients assessed to be at high risk of bleeding, CVVHD without anticoagulation provided a mean filter survival of 40.9 h (95% CI 27-54.8 h).
conclusionsRegional anticoagulation leads to longer filter survival than low dose heparin in shunt CAVHD. A regimen of no anticoagulation during femoral CAVHD leads to a filter life similar to that of low dose heparinization. During CVVHD, regional anticoagulation and low dose heparin are associated with similar filter survival times. In patients assessed to be at high risk of bleeding, treatment with CVVHD without anticoagulation results in adequate filter survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.